 | In a letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) provided feedback on ICER's assessment of treatments for obesity management. |
PIPC offered criticism of ICER's model for assuming the burden of obesity is limited solely to cardiovascular disease (CVD) risk, as well as for ignoring the benefits of treatment on physical function, which can have a significant impact on a patient’s quality of life. PIPC is also disappointed for ICER's reliance on both the quality-adjust-life-years (QALY) and Framingham risk equations, both of which have discriminatory implications for high-risk patient populations.
"The prevalence of obesity in the United States is growing, and it is important that appropriate interventions are available to individuals that address obesity and limit risk of associated diseases," wrote PIPC Chair Tony Coelho. "PIPC encourages ICER to make changes in its model to ensure it is representative of a real-world population, including using real world evidence where possible and recognizing the broad implications of obesity beyond risk of CVD."
"The prevalence of obesity in the United States is growing, and it is important that appropriate interventions are available to individuals that address obesity and limit risk of associated diseases," wrote PIPC Chair Tony Coelho. "PIPC encourages ICER to make changes in its model to ensure it is representative of a real-world population, including using real world evidence where possible and recognizing the broad implications of obesity beyond risk of CVD."
| icer_obesity_final_for_submission.pdf |
